Media coverage about Regulus Therapeutics (NASDAQ:RGLS) has trended somewhat positive on Monday, according to Accern Sentiment. The research firm identifies negative and positive news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Regulus Therapeutics earned a news impact score of 0.19 on Accern’s scale. Accern also assigned media stories about the biopharmaceutical company an impact score of 47.6498709889967 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
A number of analysts recently issued reports on the company. Zacks Investment Research downgraded Regulus Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, January 18th. B. Riley started coverage on Regulus Therapeutics in a report on Wednesday, March 28th. They set a “neutral” rating and a $1.00 price target for the company. Chardan Capital reiterated a “neutral” rating on shares of Regulus Therapeutics in a report on Tuesday, January 16th. Leerink Swann started coverage on Regulus Therapeutics in a report on Friday, January 5th. They set an “outperform” rating and a $2.00 price target for the company. Finally, BMO Capital Markets set a $1.00 price target on Regulus Therapeutics and gave the stock a “hold” rating in a report on Thursday, March 8th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and two have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $2.00.
Regulus Therapeutics stock traded down $0.02 during midday trading on Monday, reaching $0.65. 256,904 shares of the company’s stock were exchanged, compared to its average volume of 633,673. Regulus Therapeutics has a 52 week low of $0.63 and a 52 week high of $1.95. The stock has a market capitalization of $69.39, a P/E ratio of -0.68 and a beta of 1.70.
Regulus Therapeutics (NASDAQ:RGLS) last posted its quarterly earnings results on Wednesday, March 7th. The biopharmaceutical company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.03. Regulus Therapeutics had a negative return on equity of 201.84% and a negative net margin of 99,868.07%. The business had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.02 million. sell-side analysts anticipate that Regulus Therapeutics will post -0.64 earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: This news story was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this news story on another website, it was stolen and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at https://www.dispatchtribunal.com/2018/04/09/regulus-therapeutics-rgls-receiving-somewhat-positive-press-coverage-report-shows.html.
About Regulus Therapeutics
Regulus Therapeutics Inc, a biopharmaceutical company, focuses on the discovery and development of drugs that target microRNAs to treat a range of diseases in the United States. The company uses its microRNA product platform to develop anti-miRs, which are chemically modified and single-stranded oligonucleotides.
Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.